Adeno-associated viruses (AAVs) are now the foremost gene delivery vehicles for numerous therapeutic and investigational uses. The diverse libraries of AAV capsids project led by Protheragen has successfully synthesized methods for creating extensive libraries of AAV capsid variants with different transduction properties engineered.
Adeno-associated virus (AAV) libraries are collections of viral vectors with different capsid proteins, which are the outer protein shells of AAV. These capsids defined the tropism, efficiency, and specificity of AAV-mediated gene delivery. From a scientific perspective, AAV capsid libraries constitute an invaluable resource for investigators working in gene therapy because these catalysts help them isolate and customize appropriate viral changeable that would have maximum access into the desired cell or tissue.
Fig.1 AAV2 capsid library design. (Marques A. D., et al., 2021)
Advancements in the creation of AAV capsid libraries stem from the requirement for vectors with better attributes such as higher transduction efficiency, lower immunogenicity, and more precise tissue targeting. Such variational libraries serve as a resource for testing and identifying AAVs that surpass the shortcomings posed by naturally existing serotypes, thus broadening the possibilities for gene therapy applications.
AAV capsid libraries exhibit diversity, which comes from random mutagenesis, directed evolution, and DNA shuffling. Such diversity is beneficial in screening for candidate therapeutics because a wide range of capsids can be tested to isolate those with desirable properties for particular uses. The assessment is done via high-throughput methods that measure transduction efficiency and specificity in relevant cell or animal models for each capsid variant.
With the aim of achieving diverse viral vectors suitable for gene therapy, Protheragen utilizes numerous sophisticated approaches to develop and apply AAV capsid libraries.
Selection of AAV Serotypes
The procedure starts with the selection of AAV serotypes considering their tissue tropism, transduction efficacy, and availability of antibodies for the specific AAV subtypes. This is important because it sets the initial groundwork for the diversity within the library and how it can be utilized.
Identification of Variable Regions
We move on to locate variable regions within the AAV capsid sequence, which determine, with some other factors, the efficiency in tropism and transduction of the vector. These areas are often situated on the surface of the capsid where receptors bind to cells and enable penetration.
Introduction Of Diversity Through Peptide Insertion
To create a diverse library using these variable regions, we use both random insertion as well as replacing sections with random sequences. Replacement involves inserting specific amino acids or sequences. With this approach, we are able to test out both large and subtle alterations in changes made to the capsid structure.
Establishing the Length of Random Peptide Inserts
The length of random peptide inserts is usually defined by the intended diversity of the library, the protein or interaction of interest, as well as any functional and structural limitations. Protheragen performs pilot studies to determine optimal insert lengths for different application types to maximize research objectives.
Designing AAV Capsid Expression Strategies
Protheragen chooses an appropriate promoter for achieving optimal levels of capsid expression. The promoter governs transcription of the capsid gene and expression with its specificity and strength. For our AAV capsid libraries, we ensure robust expression during evolution and production phases by employing a CAG/P40 hybrid promoter.
Determining AAV Capsid Library Complexity
Lastly, we focus on maintaining the AAV capsid library complexity, which is based on the number of different variants within the AAV capsid pools. Compound heterozygosity broadens the chances of discovering exceptionally functional variants with attributes such as targeted delivery to specific tissues, evasion of immune response, and higher transduction rates.
Drawing on our extensive expertise, we can design and construct tailored AAV capsid libraries based on our client's specific requirements. This includes targeting particular cell types, species, or disease indications of interest. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Our AAVLinkTM platform is at the forefront of adeno-associated viral (AAV) vector development, leveraging our extensive expertise and state-of-the-art technologies to drive innovation in gene therapy.
